The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine
|
|
- Dwain Shepherd
- 5 years ago
- Views:
Transcription
1
2 The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine Oncologica addresses this new era of precision medicine by exploiting state of the art molecular profiling enabling a patient s tumour to be matched directly with the most appropriate molecular targeted therapy. Oncologica s semiconductor profiling technology reduces the number of tests required for comprehensive tumour analysis, delivers faster results and at a much lower cost.
3 4 5 THE FIRST LABORATORY IN EUROPE TO OFFER THE ONCOMINE FOCUS ASSAY FOR PERSONALISED ONCOLOGY NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY Our scientists and clinicians utilise state-of-theart next generation semiconductor sequencing technology (NGS) to rapidly detect actionable mutations in patients tumour samples to precisely match these alterations with new generation targeted therapies. Our targeted next generation sequencing assay enables simultaneous detection of thousands of genetic variants across 52 genes relevant to solid tumours. Targeted actionable hotspots include SNVs, indels, CNVs and gene fusions. Oncologica carries out DNA sequencing of patients tumour samples using semiconductor chip technology directly translating chemically encoded information (A, C, G, T) into digital information. Semiconductor sequencing has major advantages over other sequencing technologies because it can be used to sequence low DNA/RNA input FFPE biopsy samples with high throughput and at a reduced cost. The Oncofocus Assay, a targeted sequencing platform, is designed to detect actionable mutations in cancer genes targeted by onmarket oncology drugs or treatments in Analysis of the output from the Oncofocus assay is performed using the Oncomine Knowledgebase Reporter, an analytical system used to identify and prioritise potential Nucleotides flow sequentially over an Ion semiconductor chip One sensor per well per sequencing reaction Direct detection of natural DNA extension Millions of sequencing reactions per chip Fast cycle time, real time detection clinical trials. Intelligent design is driven by treatment strategies. The knowledgebase the Oncomine Knowledgebase, the world s largest curated compendium of cancer reporter enables Oncofocus detected variants to be linked to over 270 targeted therapies Ion semiconductor chip genomic information, including content aligned to approved therapies, current dntp practice guidelines and open clinical trials. H + C NGS T G A sensing layer sensor plate bulk drain source silicon substrate To column receiver Rothberg J.M. et al Nature doi:10/1038/nature10242 DNA Ions Sequence
4 6 7 Comprehensive analysis of major cancer driver genes in one single workflow dramatically reducing the cost of molecular profiling and accelerating reporting times Reduced number of tests that cancer patients require NGS semiconductor platform uses low DNA/RNA input (10ng) from FFPE samples enabling detection of actionable variants in fine needle biopsies and core needle aspirates Generates a comprehensive picture of actionable mutations providing the clinician with a detailed molecular blueprint for optimal therapy choices and improved patient outcomes Prevent the unwarranted prescribing of expensive targeted therapies to patients unlikely to benefit from such treatments Delivering New Generation Molecular Profiling for cancer targeted therapies to optimize treatment efficacy Identification of specific mutations known to be associated with response or resistance to targeted therapies Identification of new driver mutations following relapse allowing a switch to additional more appropriate targeted therapies Identification of driver mutations and linked therapies in rare tumour types for which treatment protocols are limited Molecular profiling conducted on routine diagnostic histological samples (formalin fixed paraffin embedded specimens) and liquid biopsies including circulating tumour DNA and circulating tumour cells (ctdna and CTCs)
5 8 9 TARGETED NGS FOR ALL SOLID TUMOUR TYPES TARGETED TREATMENTS The fully integrated Oncomine Focus Assay and linked Oncomine TM Knowledgebase Reporter informatics pipeline provides unparalleled information regarding an individual s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents. TUMOUR TYPE GENETIC VARIANTS TARGETED THERAPIES 35 genes and hundreds of variants tested in this tumour type Over 110 potential treatments in this tumour type KIT FUSION ROS1 FUSION Breast Bladder Colorectal Kidney Oesophagus Glioblastoma Head and Neck EGFR MUTATION NTRK2 MUTATION FGFR3 FUSION PIK3CA AMPLIFICATION NTRK3 MUTATION CABOZANTINIB AFATINIB VORINOSTAT DASATINIB MELANOMA Endometrial Mesothelioma Non Small Cell Lung Cancer Ovarian Gastric Osteosarcoma Pancreatic Liver Skin Soft Tissue Sarcoma Testicular Prostate Small Cell Lung Cancer PDGFRA MUTATION EGFR MUTATION BRAF MUTATION NTRK2 FUSION SMO MUTATION ERBB2 AMPLIFICATION ALK FUSION ERBB2 AMPLIFICATION RET MUTATION BRAF MUTATION IMATINIB MESYLATE CLR-457 CRIZOTINIB VEMURAFENIB EVEROLIMUS COBIMETINIB + RG-7446 DABRAFENIB CERITINIB + CHEMOTHERAPY GIST Thyroid PDGFRA AMPLIFICATION KIT MUTATION AFATINIB TRASTUZUMAB NERATINIB CETUXIMAB ERBB2 AMPLIFICATION FGFR4 MUTATION CDKN2A MUTATION PANITUMUMAB
6 10 11 TARGETED NGS FOR ALL SOLID TUMOUR TYPES TARGETED TREATMENTS The fully integrated Oncomine Focus Assay and linked Oncomine TM Knowledgebase Reporter informatics pipeline provides unparalleled information regarding an individual s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents. TUMOUR TYPE GENETIC VARIANTS TARGETED THERAPIES CDK4 MUTATION 35 genes and hundreds of variants tested in this tumour type Over 90 potential treatments in this tumour type Bladder Colorectal Kidney Glioblastoma FGFR2 AMPLIFICATION BRAF MUTATION ERBB2 AMPLIFICATION ERLOTINIB NERATINIB VEMURAFENIB Endometrial Breast Oesophagus Gastric Liver Skin Head and Neck Prostate PROSTATE PDGFRA MUTATION EGFR FUSION AXL FUSION AXL FUSION EGFR AMPLIFICATION ABL1 ABERRATION CDK4 MUTATION FGFR2 FUSION RET MUTATION AFATINIB IPILIMUMAB IMATINIB MESYLATE CRIZOTINIB + DASATINIB Mesothelioma Non Small Cell Lung Cancer Ovarian Osteosarcoma Pancreatic Soft Tissue Sarcoma Testicular Small Cell Lung Cancer AKL FUSION NTRK2 FUSION SMO MUTATION MAP2K1 MUTATION HRAS MUTATION ALK FUSION EGFR MUTATION DABRAFENIB + TRAMETINIB RIBOCICLIB JNJ CLR-457 DABRAFENIB CETUXIMAB GIST Thyroid TSC2 MUTATION MET FUSION PTCH1 MUTATION NTRK3 MUTATION CERITINIB MGCD-265 VORINOSTAT JNJ CABOZANTINIB
7 12 13 TARGETED NGS FOR ALL SOLID TUMOUR TYPES TARGETED TREATMENTS The fully integrated Oncomine Focus Assay and linked Oncomine TM Knowledgebase Reporter informatics pipeline provides unparalleled information regarding an individual s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents. TUMOUR TYPE GENETIC VARIANTS TARGETED THERAPIES 12 genes and hundreds of variants tested in this tumour type Over 30 potential treatments in this tumour type Bladder Colorectal Kidney Glioblastoma ALK FUSION EGFR MUTATION KIT MUTATION RET FUSION RET MUTATION GEFITINIB VEMURAFENIB Endometrial Breast Mesothelioma LUNG Oesophagus Gastric Osteosarcoma Liver Skin Soft Tissue Sarcoma Head and Neck Prostate Small Cell Lung Cancer ERBB2 MUTATION KRAS MUTATION MET AMPLIFICATION EGFR MUTATION CDK4 MUTATION EGFR MUTATION KRAS G12 MUTATION HRAS MUTATION ALK FUSION PTCH1 MUTATION DASATINIB CABOZANTINIB CRIZOTINIB CETUXIMAB* NIVOLUMAB IMATINIB MESYLATE CLR-457 AZD-9291 PALBOCICLIB Ovarian Pancreatic Testicular PDGFRA MUTATION TSC2 MUTATION MET FUSION ERLOTINIB DABRAFENIB AFATINIB GIST Thyroid PDGFRA MUTATION CRIZOTINIB TRASTUZUMAB + CAPECITABINE MET AMPLIFICATION BRAF MUTATION ERBB2 AMPLIFICATION DASATINIB *contraindicate
8 14 15 ONCOFOCUS PATIENT TEST REPORT PUBLISHED THERAPIES SUMMARY In this cancer type In other cancer type In this cancer type and other cancer types Contraindicated No evidence available (IV), (III), (II/III), (II), (I/II), (I) Clinical trial phase Published therapy Current FDA information NCCN Guidelines Open clinical trials for this cancer type* Oncomine Cancer Panel Patient Test Report SUBJECT INFORMATION Pre-Screening Subject No.: Subject Initials: (first/middle/last) Date of Birth: (dd/mmm/yyyy) Life Technologies Clinical Services Lab 910 Riverside Parkway, Suite 60 West Sacramento, CA Ph: (888) Fax: (855) lifelabdx.com SITE INFORMATION Investigator Name: Site ID: Date of Shipment: (dd/mmm/yyyy) Gender: M F Phone: Fax: SPECIMEN INFORMATION cetuximab panitumumab panitumumab + chemotherapy (II) regorafenib + FOLFIRI (II) sorafenib + cetuximab (II) Accession No.: Date Specimen Received: Date Reported: TEST RESULTS In this cancer type In other cancer type In this cancer type and other cancer types Mutations Amino Acid Current FDA Gene Geneotype Classification Change Information Contraindicated No evidence available Number of therapies with NCCN clinical trials in this Guideline therapies KRAS p.ala146thr c.436g>a Gain of Function 2 15 KIT p.met541leu c.1612a>c Gain of Function 1 1 MET p.asn375ser c.1124a>g Gain of Function 3 TP53 p.arg234cys c.700c>t Loss of Function 1 TP53 p.pro33arg c.98c>g Loss of Function 1 PUBLISHED THERAPIES DETAIL - NCCN GUIDELINES NCCN Guidelines information is current as of For the most up-to-date information, go to Copy Number Variations Current FDA NCCN Number of therapies with Gene Type Classification Information Guideline clinical trials in this therapies PTEN Deletion Loss of Function 5 There is no current FDA information, NCCN guidelines, or open clinical trials for the following detected copy number variations: RPS6KB1 Amplification, FLT3 Amplification, ACVRL1 Amplification, PTCH1 Deletion, CDKN2A Deletion, MYC Amplification, TERT Amplification, TET2 Deletion, VHL Deletion. Read the Full Report on Other mutations, copy number variations, or fusions of that were detected but not classified by the Oncomine Knowledgebase as a genetic driver of cancer are not listed in the results section of this report. All other genes listed in the Test Description that do not appear in the results section either did not have a detected variant or the variant is not classified as a genetic driver for cancer. Laboratory director: John E. Glassco, MD, FCAP CLIA number: 05D Life Technologies Clinical Services Lab tests are intended for clinical use. They were developed and their performance characteristics determined by the Life Technologies Clinical Services Lab, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity testing. The tests have not been cleared or approved by the United States Food and Drug Administration; however, such clearance or approval is not currently required Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation and/or its affiliate(s). cetuximab Cancer type: Colorectal Cancer Class: KRAS mutation Contraindication: Based upon lower-level evidence, there is uniform NCCN consensus (Category 2A) that patients with any known KRAS or NRAS mutation should not be treated with either cetuximab or pantitumumab. (COL-A 4 of 5, MS-34) Reference: NCCN Guideline Version Colon Cancer TEST RESULTS SUMMARY PUBLISHED THERAPIES DETAIL - OPEN CLINICAL TRIALS Mutations Gene In this cancer type In other cancer type In this cancer type and other cancer types Amino Acid Change Geneotype Classification Current FDA Information Contraindicated NCCN Guideline No evidence available Number of therapies with clinical trials in this therapies KRAS p.ala146thr c.436g>a Gain of Function 2 15 KIT p.met541leu c.1612a>c Gain of Function 1 1 MET p.asn375ser c.1124a>g Gain of Function 3 TP53 p.arg234cys c.700c>t Loss of Function 1 NCT : A Phase I Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer Class: KRAS mutation Population segment(s): Second line or greater/refractory/relapsed, Stage III, Stage IV Phase: I Published therapy: buparlisib + irinotecan Location(s): KS Contact: Stacey Purinton [ ;spurinton@kumc.edu]
9 LONGITUDINAL DYNAMIC MONITORING OF PATIENTS RECEIVING TARGETED THERAPIES SERVICE FLOW PROFILING FLOW EXAMPLE DNA+RNA extraction Sample receipt FFPE block, curl or liquid biopsy ONCOFOCUS PATIENT TEST REPORT Primary diagnosis Relapse Liquid biopsy e.g. ctdna, CTCs Construct Library ACTIONABLE DIAGNOSIS Initial profiling e.g EGFR L858R mutation Secondary profiling, e.g. EGFR T790M resistance mutation Prepare template Template enrichment DRUG RESPONSIVENESS ANALYSIS Routine histological samples Run sequence CLINICAL TRIALS INFORMATION Candidate treatment: erlotinib,gefitinib, afatinib,dacomitinib neratinib Candidate treatment: AZD-9291 Data Analysis Report generation AVERAGE TURNAROUND TIME: 10 DAYS Return of hard copy and sample Secure electronic transfer of report
10 18 19 EXAMPLES OF GENETIC VARIANTS AND TARGETED TREATMENTS Alteration Tumour type Example treatment(s) ALK fusion NSCLC ceritinib, crizotinib AKT1 mutation Multi cancer MK-2206, MSC A *BAP1 mutation Melanoma vorinostat BRAF mutation Melanoma dabrafenib, trametinib, vemurafenib BRAF mutation NSCLC dabrafenib, vemurafenib BRCA1 mutation, deletion Multi cancer rucaparib, veliparib BRCA2 mutation, deletion Multi cancer rucaparib, veliparib CCND1 amplification Multi cancer palbociclib CDK4 amplification, mutation Melanoma, NSCLC palbociclib CDK6 amplification NSCLC palbociclib *CDKN2A mutation Multi cancer crizotinib + dasatinib, palbociclib DDR2 mutation Multi cancer crizotinib + dasatinib EGFR mutation NSCLC afatinib, erlotinib ERBB2 amplification Breast cancer pertuzumab, trastuzumab ERBB2 amplification Gastric cancer trastuzumab ERBB2 amplification NSCLC afatinib ERBB3 mutation Multi cancer neratinib FGFR1-4 mutation, amplification, fusion Multi cancer GNA11 mutation Melanoma vorinostat GNAQ mutation Melanoma vorinostat BGJ-398, JNJ HRAS mutation Multi cancer binimetinib + panitumumab, BVD-523 *available soon Alteration Tumour type Example treatment(s) IDH1 mutation Multi cancer AG-120 KIT amplification Melanoma dasatinib KIT mutation Melanoma imatinib mesylate KIT mutation GIST imatinib, sunitinib, regorafenib KRAS mutation Colorectal cancer cetuximab, panitumumab contraindicated KRAS mutation Multi cancer various MEKi combinations MET amplification NSCLC crizotinib MET mutation Multi cancer AMG-337, crizotinib, INCB MTOR mutation Multi cancer MSC A MYCN amplification Multi cancer GSK NRAS mutation Colorectal cancer cetuzimab, panitumumab contraindicated NRAS mutation Multi cancer various MEKi combinations PDGFRA amplification Glioblastoma nilotinib, sorafenib PDGFRA mutation GIST dasatinib PIK3CA mutation Multi cancer various PI3K pathway combinations PPARG fusion Thyroid cancer pioglitazone *PTCH1 mutation Multi cancer vismodegib PTEN deletion, mutation Multi cancer various PI3K pathway combinations RET fusion NSCLC cabozantinib RET mutation NSCLC, Thyroid cancer ponatinib, sunitinib ROS1 fusion NSCLC crizotinib SMO mutation Multi cancer vismodegib STK11 mutation Multi cancer MSC A TP53 mutation Multi cancer MK-1775, MK-8242 *TSC1,2 m utation Multi cancer MSC A Approved - FDA labels Approved - NCCN Investigational - Trials
11 20 ONCOLOGICA TEST MENU FOR PERSONALISED ONCOLOGY ONCOFOCUS PANEL 52 GENE LIST SUMMARY Oncofocus Test Comprehensive NGS targeted panel for precision therapy Oncofocus was developed as part of the US NCI-MATCH (Molecular Analysis for Therapy Choice) program for precision oncology involving 2400 NCI-affiliated hospitals, >700,000 patients samples, 120 phase 3 and 215 early phase trials. The Oncofocus test utilises state of the art semiconductor technology to rapidly sequence DNA/ RNA extracted from routine FFPE surgical biopsy material. The assay is designed to detect thousands of genetic alterations including SNPs, indels, CNVs and fusions across 52 of the major cancer driver genes linked to solid tumours. The data generated by the Oncofocus test is analysed using the Oncomine Knowledgebase informatics pipeline, the world s largest curated compendium of cancer genetic information, enabling genetic alterations/variants to be linked to over 280 targeted therapies. Targeted therapies include all classes: -FDA approved therapies, -national comprehensive cancer network (NCCN) guideline referenced therapies and -therapies entered into US, EU and Japanese phase I, II and III clinical trials. 52 Genes relevant to solid tumors to detection of thousands of variants gene alterations aligned 21 over HOTSPOT GENES AKT1 ALK AR BRAF CDK4 CTNNB1 DDR2 EGFR ERBB2 ERBB3 ERBB4 ESR1 FGFR2 23 FUSION DRIVERS COPY NUMBER VARIANTS FGFR3 GNA11 GNAQ HRAS IDH1 IDH2 JAK1 JAK2 JAK3 KIT KRAS MAP2K1 MAP2K2 MET MTOR NRAS PDGFRA PIK3CA RAF1 RET ROS1 SMO ALK AR BRAF CCND1 CDK4 CDK6 EGFR ERBB2 FGFR1 FGFR2 FGFR3 FGFR4 KIT KRAS MET MYC MYCN PDGFRA PIK3CA ABL1 AKT3 ALK AXL BRAF EGFR ERBB2 ERG ETV1 ETV4 ETV5 FGFR1 FGFR2 FGFR3 MET NTRK1 NTRK2 NTRK3 PDGFRA PPARG RAF1 RET ROS1 targeted therapies and many more undergoing clinical trials CNV FUSION HOTSPOT HOTSPOT + FUSION HOTSPOT + CNV Additional tests for targeted therapies available. Please visit CNV + FUSION HOTSPOT + CNV + FUSION
12 22 MANAGEMENT TEAM Professor Gareth Williams and Dr Marco Loddo are Co-founders and Directors of Oncologica and have in-depth knowledge and expertise in diagnostic oncopathology, translational biology, biomarker discovery and drug development. Kitty Williams is the Senior Commercial Manager and is responsible for providing advice and implementation on commercial and corporate matters Philippa Jones is the Senior Operations Manager and directs the tissue based diagnostic services of the company. Katherine Marquis is the Senior Biomedical Scientist who directs the precision oncology services for targeted therapies TELEPHONE MAIL Keeda-Marie Snelson is the Lead Clinical Scientist with extensive expertise in the analysis of cancer genetic variants of clinical prognostic and predictive significance. Rebecca Cadman is the Business Development Manager and is responsible for exploring new market opportunities and providing comprehensive support for existing clients. Read more about our team by visitng Suite The Science Village, Chesterford Research Park, Chesterford, Cambridge, CB10 1XL
13 Suite The Science Village, Chesterford Research Park, Chesterford, Cambridge, CB10 1XL
Oncofocus. Patient Test Report
Oncofocus Patient Test Report Oncofocus Patient Test Report Oncologica UK Ltd, Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL www.oncologica.com - Tel: +44 (0)1223 785327
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationOncomine Focus assay panel and Oncomine Knowledgebase Reporter.
Oncomine Focus assay panel and Oncomine Knowledgebase Reporter. How it can help to identify relevant alteration and early phase trials. Dr Isabelle SOUBEYRAN Dr Emmanuel KHALIFA Molecular Pathology Unit
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationIllumina s Cancer Research Portfolio and Dedicated Workflows
Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationIMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY
Madrid, Spain IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Dr. JL Rodríguez Peralto NGS Ion Torrent Oncomine Focus Assay - Implementation experience for EGFR mutation detection
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Katherine Marquis Oncologica UK Ltd Date: 05 Aug 2016 1 of 18 Comment: The DNA and RNA extracted from this sample were of
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson BMS: Tiffany Haddow Date: 30 Nov 2016 1 of 11 Comment: The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationTumor monitoring in a drop of blood.
Tumor monitoring in a drop of blood. PRECISION MEDICINE STARTS WITH A FINGER STICK. circulogene.com Circulogene Theranostics solution to liquid biopsy. Novel cell-free DNA enrichment method for high quantity
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson BMS: Tiffany Haddow Date: 14 Dec 2016 1 of 18 Comment: The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationJennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA
Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationWhat is the status of the technologies of "precision medicine?
Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 24 May 2017 1 of 14 ONC17 Surname Requesting Clinician Forename DOB Date requested Gender Histology
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More informationDetecting Oncogenic Mutations in Whole Blood
WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 29 Mar 2017 1 of 8 Surname Forename DOB Gender Histology # Primary site Tumour subtype Tissue Type
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 06 Jun 2017 1 of 13 ONC17 Surname Requesting Clinician Forename DOB Date requested Gender Female Histology
More informationComprehensive genomic profiling for various solid tumors
Content Highlight Test Specification Test Content Performance Validation Test Report I II III IV V The NovoPM TM comprehensive cancer genomic profiling test Comprehensive genomic profiling for various
More informationRelevance of Innovative Trial Design Today. Basket of Baskets and other Innovative Clinical Trials
Relevance of Innovative Trial Design Today Basket of Baskets and other Innovative Clinical Trials Outline Precision Medicine Clinical Trials Evolving Field Classic industry-sponsored design: single drug,
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 04 May 2017 1 of 28 Surname Forename DOB Gender Histology # Primary site Tumour subtype Tissue Type
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 08 Feb 2017 1 of 6 Comment: The DNA and RNA extracted from this sample were of optimal quantity. The
More informationSecuenciación masiva: papel en la toma de decisiones
Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.
More informationDiagnostica Molecolare!
Diagnostica Molecolare! Aldo Scarpa Unità Diagnostica Molecolare Azienda Ospedaliera Universitaria Integrata di Verona e ARC-NET Centro di Ricerca Applicata sul Cancro PDTA CARCINOMA POLMONARE - IL PAZIENTE
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson BMS: Tiffany Haddow Date: 14 Dec 2016 1 of 18 Comment: The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Katherine Marquis Oncologica UK Ltd Date: 27 Jun 2016 1 of 36 Comment: The DNA and RNA extracted from this sample were of
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Keeley Monsen Date: 26 May 2017 1 of 26 ONC17 Surname Requesting Clinician Forename DOB Date requested Gender Male Histology
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson BMS: Tiffany Haddow Date: 22 Dec 2016 1 of 4 Comment: The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationClick to edit Master /tle style
Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationThe NCI- MATCH (EAY131) Precision Medicine Trial: Lessons Learned and Status Update
The NCI- MATCH (EAY131) Precision Medicine Trial: Lessons Learned and Status Update Robert L. Comis, MD Oslo Cancer Cluster Cancer Crosslinks 2016 October 19, 2016 1 1 NCI-Molecular Analysis for Therapy
More informationWhat is Precision Medicine?
Precision Medicine and the Treatment of Cancer Carlos L. Arteaga, MD Center for Cancer Targeted Therapies VICC Breast Cancer Program Vanderbilt-Ingram Cancer Center (VICC) Departments of Medicine and Cancer
More informationDr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
More informationSOMATIC MUTATION FREQUENCIES MONITORING
CANCER PRODROMAL STAGE ASSESSMENT SOMATIC MUTATION FREQUENCIES MONITORING PREVENTION PROGRAM spin off SOLID CANCER PRODROMAL STAGE ASSESSMENT By yearly monitoring the occurrence of cancerassociated mutations
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationNext Generation Sequencing: What Will it Mean for the Pathologist?
Next Generation Sequencing: What Will it Mean for the Pathologist? Christopher Corless, MD, PhD Professor of Pathology, Oregon Health & Science University Chief Medical Officer, Knight Diagnostic Laboratories
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Senior BMS: Katherine Marquis Date: 04 Apr 2016 17:01:50 PM 1 of 18 Comment: The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus assay on which
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Panel Testing of Cancers to Identify Targeted Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_panel_testing_of_cancers_to_identify_targeted_therapies
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationOncology Drug Development
Oncology Drug Development Advantages and challenges of using stratified clinical studies Simon J Hollingsworth The 18th Anti-Tumour Drug Development Forum 21 February Japan Stratified Medicine In The Clinic
More informationProtein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies
Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Katherine Marquis Date: 05 Oct 2016 1 of 8 The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus
More informationKEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
More informationSample Report. Result: POSITIVE Mutations Detected: NRAS-G13V, TP53-R282W, TP53-G245D, TP53-R175H, BRAF-V600M, MSI-High
Sample Report PATIENT INFORMATION Name: DOB: Age: Sex: Address: Doe, John 09/04/1969 49 Male South Plainfield, NJ, 07080 SAMPLE INFORMATION Date Collected: Date Received: Date of Report: lab ID: Testing
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 04 May 2017 1 of 28 Surname Forename DOB Gender Histology # Primary site Tumour subtype Tissue Type
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 24 May 2017 1 of 14 ONC17 Surname Requesting Clinician Forename DOB Date requested Gender Histology
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 04 May 2017 1 of 13 Surname Forename DOB Gender Histology # Primary site Tumour subtype Tissue Type
More informationResult: POSITIVE Mutations Detected: EGFR-T790M, EGFR-L858R
11427 Reed Hartman Hwy Cincinnati, OH 45241 PATIENT INFO SAMPLE Name: John Smith DOB: 4/22/1973 Age: 43 Sex: Male Address: 126 Corporate Blvd. South Plainfield, NJ 07080 Date Collected: 12/22/2015 Date
More information